Scilex Holding Company Announces Market Research Results... | SRNE Message Board Posts


Sorrento Therapeutics, Inc.

  SRNE website

SRNE   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  1942 of 2010  at  11/22/2023 5:59:43 PM  by

put_lipstick_on_this_pig


Scilex Holding Company Announces Market Research Results...

 

Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB® with Potential Advantages Compared to Calcitonin Gene-Related Peptide (CGRP) Products and Triptan Therapy

 
  • Migraines affect over 37 million Americans, according to the Migraine Research Foundation (MRF).1

  • Migraine-related pain is the third most prevalent illness in the world.1

  • According to the Global Burden of Disease study, migraines are the second leading cause of disability worldwide.1

  • A recent market research study (n=150) of Neurologists, Headache Specialists and Primary Care Physicians revealed that 93% of clinicians treating migraine have moderate to extremely high unmet needs for alternatives to triptan therapy.2

  • Elyxyb® (celecoxib oral solution) profile is preferred by physicians to address migraine attacks that often involve throbbing, nausea, sensitivity to light and sound, and other symptoms that can last extended periods of time often ranging from 4 to 72 hours.1

PALO ALTO, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the key product attributes of ELYXYB® meet the high unmet needs of clinicians treating patients with acute migraine, with and without aura, in adults, based on the results from a recent market research study.

A recent market research study (n=150) of Neurologists, Headache Specialists and Primary Care Physicians revealed that 93% of clinicians treating migraine have moderate to extremely high unmet needs for alternatives to triptan therapy.2 Clinicians stated their desire for fast and safe alternatives for two large pools of acute migraine patients – those who have an insufficient response to triptan therapy, and those who have contraindications to triptan use. ELYXYB’s product profile mapped with a high degree of certainty to these stated unmet needs. In clinical studies, patients treated with ELYXYB® demonstrated pain relief in as little as 15 minutes, and significant pain relief compared to placebo within 45 minutes in nearly 50% of patients. Approximately 34% of patients were pain free at two hours.3 Notably, these data are well differentiated from two other new oral migraine medications of a different class, calcitonin gene-related peptide (CGRP) receptor antagonists. Recent data from a post hoc analysis presented at the Brain Week Conference in Las Vegas showcased that ELYXYB® had higher pain freedom rates from 60 minutes through 3 hours post-dose compared to ubrogepant 100 mg and rimegepant 75 mg.4 As a low-dose COX-2 inhibitor, ELYXYB was safe and well-tolerated in large Phase III clinical studies of 1,253 patients.3 The most common adverse reaction was dysgeusia (3% of patients on ELYXYB vs 1% on placebo).3 Unlike triptans, ELYXYB is not contraindicated in patients with cardiovascular conditions.5

For more information on ELYXYB, including Full Prescribing Information, refer to the Exhibits hereto and visit ELYXYB.com.
 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...